Summary.-The effect of misonidazole (MISO) on the cytotoxicity of cyclophosphamide (CY) was investigated in the mouse.
IT IS WELL KNOWN that hypoxia protects cells from the cytotoxic effects of radiation. Hypoxic cells in solid tumours are therefore considered to be a problem in the treatment of cancer by radiotherapy. There are also reasons why hypoxic cells may be protected from chemotherapy. Hypoxic cells and cells that are distant from blood vessels tend to proliferate slowly (Tannock, 1968; Koch et al., 1973; Bedford & Mitchell, 1974; Hirst & Denekamp, 1979 ) and may, therefore, be resistant to most chemotherapeutic agents, w^hich are more toxic to rapidly dividing than to slowly dividing cells. Hypoxic tumour cells may also receive lower concentrations of drugs, because of their distance from patent blood vessels. It has also been reported that hypoxia per se protects mammalian cells against the cytotoxic action of bleomycin (RoizinTowle & Hall, 1978) and actinomycin D (Adams, 1979) .
Electron-affinic agents, such as the 2- niitroimidazole, misonidazole [1-(2-nitroimidazole -1 -yl) -3 -methoxypropan-2 -ol; Ro-07-0582, MISO], have been shown to be effective sensitizers of the cytotoxic effects of radiation on hypoxic cells in vitro and on tumours in vivo (Adams, 1977) , and clinical trials of MISO in combination with radiation therapy are in progress in * I'liesent address: AIRC Cyclotron Unit, Hammersmnith Hospital, Dai Caiie Road, Loii(lo0I XVI 2 OHS.
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many centres (Thomlinson et al., 1976; Dische et al., 1977; Urtasun et al., 1977) . Recently, Rose et al. (1979 Rose et al. ( , 1980 have shown that the cytotoxic effects of 2 alkylating agents, melphalan and cyclophosphamide (CY), are enhanced by MISO in mice. The response of the Lewis lung carcinoma was enhanced to a greater extent than marrow, suggesting an increased therapeutic ratio for the combined therapy.
In the present study the effect of MISO on the response of the RIF-1 tumour to CY was investigated in mice. The endpoints used to assess damage to the tumour were growth delay in situ, and cell survival assayed by plating in vitro after treatment in vivo. To assess a possible therapeutic gain, the responses of marrow stem cells and white blood cells (WBC) were also measured over the dose range used for the tumour studies.
Some of the possible mechanisms for the sensitization of this tumour to CY by MISO were also investigated.
METHODS

Tumour studies
The RIF-1 tumour used in the present study is a non-immunogenic sarcoma in its syngeneic host, the C3H/Km mouse, which has been developed for in vivo-in vitro assay (Twentyman et al., 1980) . Solid tumours were produced in 3-4-month-old female C3H/Km mice by inoculating 2 x 105 cells in a volume of 0 05 ml into the base of the gastrocnemius muscle. Tumour growth was followed by measuring 2 leg diameters at right angles, using a specially made Plexiglas gauge. Tumour volume was estimated from a calibration curve of tumour weight (-tumour volume) plotted as a function of the product of the 2 leg diameters (Twentyman et al., 1979) . Drug treatments were given when the tumours were 300-600 mg.
The response to drug treatments was investigated by 2 methods. For the growthdelay assay, 10 animals were included in each treatment group and tumours were measured 3 times a week. CY caused cessation of growth or regression, both of which were followed by regrowth at rates identical to those in untreated mice. To compare treatments the number of days required to reach 4 x the mean treatment volume was determined from growth curves plotted for each animal. Geometric means and standard errors were calculated for each treatment group, as the growth delays for individual tumours were log-normally distributed.
For the cell-survival assay, tumours were excised 24 h after treatment. This interval was chosen as a compromise to allow most or all of any potentially lethal CY damage to be repaired whilst not allowing much time for proliferation of surviving cells (Twentyman, 1977 (Twentyman, , 1979 Begg et al., 1980) . Two to four tumours were pooled and a single-cell suspension was prepared by mincing the tissue and incubating it with an enzyme "cocktail" of 0-027% collagenase, 0.02% DNAse and 0.05% pronase. The cells which excluded trypan blue were counted with a haemacytometer (cell yield 2 x 108/g) and appropriate dilutions were plated into polystyrene Petri dishes containing complete Waymouth's medium which included 15% foetal calf serum. Colonies of at least 50 cells were counted after 13 days' incubation at 37°C. The plating efficiency (PE) for control tumours was -30%. Surviving fractions were calculated from either PE or numbers of clonogenic cells per gram of tumour. There was no significant difference between the results obtained by the 2 methods of calculation, so only surviving fractions estimated from PE are shown in the figures. Details of the method have been given elsewhere (Twentyman et al., 1980; Brown, 1977) .
Normal-tissue studies
Marrow stem cells.-The survival of marrow stem cells was determined using the spleencolony assay (Till & McCulloch, 1961) . Marrow was removed from both femurs of 5-10 C3H/Km mice 24 h after treatment. The survival of marrow stem cells did not alter significantly when the interval between the drug treatments and excision was varied from 1 to 24 h (data not shown). An appropriate number of marrow cells which excluded trypan blue were injected in 0-2 ml into the tail veins of 8-10 preirradiated (8-5 Gy whole body) recipients. (Twentyman et al., 1980) . Combining this dose of CY with the doses of MISO used in this study had no effect on animal survival. However, 5/9 mice died after 5 daily treatments of 300 mg/kg MISO combined with 50 mg/kg CY (total dose of MISO and CY. 1500 and 250 mg/kg respectively) compared with 2/9 after 5 daily treatments of 50 mg/kg CY (same total dose) given with saline.
RESULTS
Response of RIF-1 tumours
Effect of cyclophosphamide dose.-Mice bearing RIF-1 tumours were injected with MISO (750 mg/kg) or saline 30 min before various single doses of CY. The effect on the tumour response to CY is seen in Fig. 1 Effect of interval between drugs.- Fig. 2 shows the effect of varying the time between MISO and CY treatments. Growthdelay and cell-survival assays gave similar results. Enhancement of the response to CY was seen if the drugs were given simultaneously, but the maximum effect was observed when MISO was given 0-5-2 h before CY. The interaction subsequently decreased and was lost by [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] h. In one experiment (data not shown) 750 mg/kg MISO was given at various times after 50 mg/kg CY. The interaction, as measured by cell survival, was lost if the interval between CY and MISO was 30-60 min.
Effect of misonidazole dose.-Various doses of MISO were given 30 min before a 50 mg/kg dose of CY. The results are shown in Fig. 3 . For growth delay, enhancement reached a plateau at a MISO dose of 250 mg/kg. For tumour-cell survival, enhancement increased with dose of MISO, with a suggestion of a plateau at 500 mg/kg.
There is an apparent discrepancy be- 10-3 or combined with MISO is shown in Fig. 4 . The dose of MISO (300 mg/kg) was given 30 min before each CY dose, and caused no animal toxicity when given in the 5 daily fractions with any CY dose. Enhancement was found at doses of CY greater than -10 mg/kg/day (i.e., total dose , 50 mg/kg). Enhancement ratios are given in Table II Fig. 6 . The experiments were carried out on both tumour-bearing and non-tumour-bearing animals, and as no consistent difference was seen between the responses, the data from both series of experiments were pooled. Counts of total WBC and of the 2 major subpopulations, lymphocytes and neutrophils, are shown. MISO alone reduced the number of circulating WBC by 20%, an effect entirely due to depletion of the neutrophil population. Lymphocytes were unaffected by MISO alone at the dose used (750 mg/kg). With increasing dose of CY, the total number of WBC decreased exponentially. Both lymphocytes and neutrophils were affected, but neutrophils showed much greater sensitivity. No neutrophils were seen in any of the blood smears after 60 mg/kg of CY plus MISO. The combination with MISO reduced the number of WBC at all doses of CY, but the effect was consistent with direct MISO cytotoxicity, and did not change the slope of the doseresponse curve.
Study of mechanisms
Metabolic effects.-Thermocouples were used to measure rectal temperatures in unanaesthetized C3H/Km mice for 12 h after various drug treatments. The effect of MISO was compared with that of SR-2508, a 2-nitroimidazole of equal electronaffinity but lower toxicity (Brown & Workman, 1980) . In contrast to MISO, SR-2508 undergoes little or no oxidative metabolism in vivo (White et al., 1980) . MISO at 750 mg/kg alone or combined with CY caused a temperature drop of about 5TC, whereas SR-2508 given in the same molar doses (800 mg/kg) had no effect on temperature (Fig. 7) . SR-2508, however, enhanced the cytotoxicity of CY to RIF-1 tumour cells, as shown in Fig. 8 interval between sensitizer and CY was increased occurred more rapidly for SR-2508, as might be expected, since the elimination half-life of SR-2508 is considerably less than that of MISO (Brown & Workman, 1980 alone, enhances the cytotoxic effect of CY in vivo. A comparison of enhancement ratios (ER) for the different tissues and endpoints used is shown in Fig. 10 . For single treatments, MISO at 750 mg/kg was given at the optimal time of 30 min before injection of CY (Fig. 2) . The ER for tumour-growth delay was -2 0 for CY doses up to 75 mg/kg. Above these doses there was no additional sensitization, so that ER steadily decreased with increasing doses of CY. Because the RIF-1 tumour cells were very sensitive to combined treatment, ERs could only be determined for low doses of CY in the in vivo-in vitro assay. The ERs obtained from these experiments were less than those obtained for comparable doses using growth delay as the endpoint, and showed more variability between experiments. This will be discussed in more detail below. Both the endpoints used to assess the sensitivity of normal tissues to the different treatments involved populations of the haemopoietic system. However, the results for marrow stem cells (CFU-S) as assayed in the spleen-colony assay, and for mature white cells in the peripheral blood, showed some differences. Whereas MISO alone at 750 mg/kg had no cytotoxic effect on marrow stem cells, it reduced the number of neutrophils, so that the total WBC count decreased by 20%. The lack of an effect of MISO alone at high doses on mouse CFU-S is in agreement with the findings of Turner et al. (1980) , though the same group has reported preliminary findings that therapeutic doses of MISO in patients cause a significant reduction in CFU-S assayed in vitro (Allalunis et al., 1979) . In neither of these studies was the effect on the peripheral white count noted. However, significant neutropenia has been reported in women treated for vaginal trichomoniasis with total doses of 7.5 g metronidazole given over 10 days (Lefebvre & Hesseltine, 1965) .
When MISO was combined with CY, a slight enhancement of the cytotoxicity to CFU-S at CY doses > 100 mg/kg was seen, but there was no modification of the response of WBC in general or neutrophils in particular to CY. The lack of correlation between the 2 cell populations probably reflects the complexity of the divisions and differentiation which occur during haemopoiesis. In either case, any increased effect seen by the addition of MISO was much less than that observed in the RIF-1 tumour, so that there was a positive therapeutic gain.
MISO also enhanced the growth delay of the RIF-1 tumour after fractionated doses of CY. In contrast to the results for single treatments, however, ERs for repeated treatment increased with increasing CY dose, and the maximum ER at 50 mg/kg/fraction of CY with MISO was less than that for single treatments.
Enhancement by MISO of the response to CY has been observed by other authors in 6 murine tumours (Clement et al., 1980; Martin & McNally, personal communication; Rose et al., 1980; Tannock, 1980; Twentyman, 1981) . In general a therapeutic gain has been obtained by combining MISO and CY, maximum ERs for tumours being about 2, compared with 10-105 for lethality (Clement et al., 1980; Martin & McNally, personal communication; Twentyman, 1981) , marrow stem-cell survival (Clement et al., 1980; Rose et al., 1980; and bladder epithelium (Martin & McNally, personal communication) . Tannock (1980) , however, has concluded from his experiments with the KHT tumour that there is no therapeutic gain in adding MISO to CY. His conclusion was based on comparisons of weight loss, mouse toxicity and tumour growth delay after injection of 200 mg/kg CY alone or after 75 mg/kg CY combined with 1000 mg/kg MISO. We feel, however, that this is a misleading conclusion. Whereas there may well be no therapeutic gain at 200 mg/kg of CY, this does not preclude one at lower doses. In fact our data show a high therapeutic gain at doses of less than 75 mg/kg of CY alone, but no gain at doses in excess of 150 mg/kg (Fig. 10) . Such doses are higher than clinical usage, and the greater tumour effect than marrow toxicity at lower doses of CY suggests that the two agents may be used to therapeutic advantage in the clinic. The first possibility (selective sensitization of hypoxic cells) could explain the differential effect of combined treatment on tumours and normal tissues, since there are hypoxic cells in tumours but not in normal tissues. The dependence of ER on CY dose, however, is not expected for sensitization of a small population of resistant hypoxic cells. By analogy to radiation damage, for which it is established that MISO sensitizes only radioresistant hypoxic cells, one might predict an increase in ER to a plateau with increasing CY dose. Actually there was a decrease in ER as the dose of CY increased. The same absence of further sensitization when MISO was added to doses of CY above -50 mg/kg has been seen for the RIF-1 tumour by Twentyman (1981) , and for the EMT6 tumour by ourselves (Brown et al., in preparation) . The fact that this result is different from that when MISO is combined with radiation, suggests that MISO does not sensitize only hypoxic cells to the cytotoxic effect of CY.
The second possibility (that MISO selectively kills the hypoxic cells which are resistant to CY) can be ruled out by 2 observations. First, such an effect would not produce a constant enhancement by MISO of the response to low doses of CY. Second, no cytotoxicity to the tumours was seen with MISO alone, either by the in vivo-in vitro assay (Fig. 1) or by histological examination of the treated tumours.
The third possibility (that MISO could change the pharmacokinetics of CY, leading to a prolongation of active metabolites in the serum) has received support from Tannock (1l980) . This investigator has shown that MISO delays the loss of active metabolites of CY, by testing the cytotoxicity of serum from treated mice against CHO cells in vitro. -However, although this might account for the small enhancement of the killing of CFU-S seen at high CY doses, it seems difficult to explain the differential effect on tumour cells and normal cells, seen by ourselves and others, in these terms. Additional evidence against this mechanism is the possibility of effects on CY pharmacokinetics by competition between the drugs for catabolic sites or from a general lowering of metabolic rates by hypothermia. Since it is probable that both CY and MISO undergo oxidative metabolism by liver microsomal mixed-function oxidases, and MISO is known to cause a reduction in body temperature, heart and respiration rates in the mouse (Gomer & Johnson, 1979; Conroy et al., 1980) , such a mechanism might appear reasonable. However, our finding that the 2-nitroimidazole radiosensitizer, SR-2508, which neither undergoes oxidative metabolism (White et al., 1980) nor causes a temperature decrease in mice (Fig. 7) , sensitizes the RIF-1 tumour to CY, suggests that interference with CY metabolism is not the primary mechanism for chemosensitization.
The fourth possibility is presented in Fig. 9 . This shows repair of potentially lethal CY damage in the RIF-1 tumour, which was inhibited by MISO. The lower ER based on cell survival than on regrowth delay is also consistent with these data. Tumours removed to assay cell survival 24 h after treatment may have repaired less potentially lethal damage (PLD) than if they had been left in situ. Inhibition of repair of PLD by MISO would thus have an apparently greater effect on growth delay than on cell survival. Inhibition of repair of potentially lethal CY damage by MISO has also been found in the WHFib sarcoma grown s.c. (Martin & McNally, personal communication) . Small WHFib lung tumours, however, showed no repair of PLD with CY. ERs for these lung tumours were less than those for the s.c. tumours, but similar to those for normal tissues. It is possible, therefore, that the sensitizing effect of MISO the cytotoxicity of CY to some tumours is due to an inhibition of repair of PLD. Not all tumours that can be sensitized to CY cytotoxicity by MISO, however, exhibit repair of CY PLD. The EMT6/St/lu tumour appears to be one such example (Brown et al., in preparation) .
Thus we cannot at this time be conclusive about the mechanism involved in sensitization of tumours to CY by MISO.
Nevertheless, our data indicate that neither a selective effect on hypoxic cells (neither sensitization nor killing), nor altered pharmacokinetics, are of primary importance and that, at least for some tumours, inhibition of repair of CY PLD by MISO may be involved.
The question of therapeutic gain must be approached with caution. The animal studies show that the combination of MIS with low doses of CY may give a therapeutic gain, when evaluated by comparing CY ERs for tumours with those for several normal tissues. Although the overall sensitivity of the WBC population does not appear to prevent the effective combination of MISO with CY, the extreme sensitivity of neutrophils to CY alone, and the fact that MISO alone at 750 mg/kg kills 500o of them, could compromise the ability to combat infection further than the total WBC would suggest.
Although we have demonstrated that the addition of MISO produces a therapeutic gain at some doses of CY, it is too early to say whether any clinical use will result from their combination. The dose of MISO (750 mg/kg) used in most present experiments is greater than the likely clinical doses. Unlike the case with radiation, however, it is not clear that peak plasma levels alone determine the magnitude of the present interaction. For example, we have shown with the RIF-1 tumour that plasma levels sustained for 5 h before CY injection give a larger ER (2*0) than the same plasma levels maintained for only 0*5 h (ER = 1.4). Thus total tissue exposure could be of importance and the 10-fold longer elimination half-life of MISO in man than in mice will give much longer tissue exposure in human than in murine tumours. In addition, we do see some enhancement of the CY effect even at MISO doses of 125 mg/kg, and these give peak plasma levels which can be attained in man. Also the possibility of enhancement of MISO-induced neurotoxicity by CY remains. In this respect, the use of less neurotoxic drugs such as SR-2508 that sensitize to CY may be an advantage.
